100423 - Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases
Welcome,         Profile    Billing    Logout  
 2 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rabe, Klaus F
PILASTER, NCT04636801 / 2020-003666-40: A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis

Recruiting
3
3435
Europe, US, RoW
Experimental: CHF6001 1600µg, Experimental: CHF6001 3200µg, Placebo
Chiesi Farmaceutici S.p.A., Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
06/25
06/25
ALLIANCE, NCT02419274: Adult Arm of DZL All Age Asthma Cohort

Recruiting
N/A
400
Europe
LungenClinic Grosshansdorf, German Center for Lung Research, Research Center Borstel
Asthma
12/25
12/30
Kalfov, Veselin
Neptuno, NCT04784559 / 2020-005951-19: Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection

Terminated
3
205
Europe, RoW
Plitidepsin, Dexamethasone, Remdesivir, Favipiravir
PharmaMar
COVID-19 Infection
03/23
03/23
TANGO, NCT06029595: Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy

Recruiting
2
464
Europe, RoW
Experimental: CHF6001 3200 μg, Placebo Comparator: CHF6001 Placebo
Chiesi Farmaceutici S.p.A.
Uncontrolled Asthma
12/25
12/25
NCT05569005: Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.

Terminated
N/A
715
Europe, Japan, US, RoW
THS use, Tobacco Heating System 3.0, Cigarette, Smoking Abstinence
Philip Morris Products S.A.
COPD, Smoking, Tobacco Use
09/24
09/24

Download Options